vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Safehold Inc. (SAFE). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $97.9M, roughly 1.8× Safehold Inc.). Safehold Inc. runs the higher net margin — 28.5% vs -0.7%, a 29.2% gap on every dollar of revenue. On growth, Safehold Inc. posted the faster year-over-year revenue change (6.5% vs 0.7%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 2.5%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.
AVNS vs SAFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $97.9M |
| Net Profit | $-1.3M | $27.9M |
| Gross Margin | 47.5% | 98.6% |
| Operating Margin | 1.4% | 27.4% |
| Net Margin | -0.7% | 28.5% |
| Revenue YoY | 0.7% | 6.5% |
| Net Profit YoY | 99.7% | 7.1% |
| EPS (diluted) | $-0.02 | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $97.9M | ||
| Q3 25 | $177.8M | $96.2M | ||
| Q2 25 | $175.0M | $93.8M | ||
| Q1 25 | $167.5M | $97.7M | ||
| Q4 24 | $179.6M | $91.9M | ||
| Q3 24 | $170.4M | $90.7M | ||
| Q2 24 | $171.7M | $89.9M | ||
| Q1 24 | $166.1M | $93.2M |
| Q4 25 | $-1.3M | $27.9M | ||
| Q3 25 | $-1.4M | $29.3M | ||
| Q2 25 | $-76.8M | $27.9M | ||
| Q1 25 | $6.6M | $29.4M | ||
| Q4 24 | $-397.3M | $26.0M | ||
| Q3 24 | $4.3M | $19.3M | ||
| Q2 24 | $1.8M | $29.7M | ||
| Q1 24 | $-900.0K | $30.7M |
| Q4 25 | 47.5% | 98.6% | ||
| Q3 25 | 48.4% | 98.5% | ||
| Q2 25 | 52.6% | 99.1% | ||
| Q1 25 | 53.6% | 98.8% | ||
| Q4 24 | 54.6% | 98.8% | ||
| Q3 24 | 54.5% | 98.8% | ||
| Q2 24 | 55.7% | 98.8% | ||
| Q1 24 | 57.1% | 98.8% |
| Q4 25 | 1.4% | 27.4% | ||
| Q3 25 | 0.1% | 25.9% | ||
| Q2 25 | -42.6% | 25.5% | ||
| Q1 25 | 6.1% | 25.9% | ||
| Q4 24 | -233.0% | 24.6% | ||
| Q3 24 | 7.0% | 17.5% | ||
| Q2 24 | 3.7% | 26.7% | ||
| Q1 24 | 2.4% | 26.4% |
| Q4 25 | -0.7% | 28.5% | ||
| Q3 25 | -0.8% | 30.5% | ||
| Q2 25 | -43.9% | 29.8% | ||
| Q1 25 | 3.9% | 30.1% | ||
| Q4 24 | -221.2% | 28.3% | ||
| Q3 24 | 2.5% | 21.3% | ||
| Q2 24 | 1.0% | 33.0% | ||
| Q1 24 | -0.5% | 33.0% |
| Q4 25 | $-0.02 | $0.38 | ||
| Q3 25 | $-0.03 | $0.41 | ||
| Q2 25 | $-1.66 | $0.39 | ||
| Q1 25 | $0.14 | $0.41 | ||
| Q4 24 | $-8.64 | $0.36 | ||
| Q3 24 | $0.09 | $0.27 | ||
| Q2 24 | $0.04 | $0.42 | ||
| Q1 24 | $-0.02 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $21.7M |
| Total DebtLower is stronger | $90.3M | $4.6B |
| Stockholders' EquityBook value | $778.2M | $2.4B |
| Total Assets | $1.1B | $7.2B |
| Debt / EquityLower = less leverage | 0.12× | 1.90× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $21.7M | ||
| Q3 25 | $70.5M | $12.1M | ||
| Q2 25 | $90.3M | $13.9M | ||
| Q1 25 | $97.0M | $17.3M | ||
| Q4 24 | $107.7M | $8.3M | ||
| Q3 24 | $89.0M | $15.6M | ||
| Q2 24 | $92.2M | $13.4M | ||
| Q1 24 | $75.8M | $11.3M |
| Q4 25 | $90.3M | $4.6B | ||
| Q3 25 | $93.4M | $4.5B | ||
| Q2 25 | $95.7M | $4.4B | ||
| Q1 25 | $98.0M | $4.3B | ||
| Q4 24 | $125.3M | $4.3B | ||
| Q3 24 | $152.6M | $4.3B | ||
| Q2 24 | $164.9M | $4.2B | ||
| Q1 24 | $167.2M | $4.1B |
| Q4 25 | $778.2M | $2.4B | ||
| Q3 25 | $778.0M | $2.4B | ||
| Q2 25 | $776.3M | $2.4B | ||
| Q1 25 | $839.4M | $2.4B | ||
| Q4 24 | $828.5M | $2.3B | ||
| Q3 24 | $1.2B | $2.3B | ||
| Q2 24 | $1.2B | $2.3B | ||
| Q1 24 | $1.2B | $2.3B |
| Q4 25 | $1.1B | $7.2B | ||
| Q3 25 | $1.1B | $7.1B | ||
| Q2 25 | $1.0B | $7.1B | ||
| Q1 25 | $1.1B | $6.9B | ||
| Q4 24 | $1.2B | $6.9B | ||
| Q3 24 | $1.7B | $6.8B | ||
| Q2 24 | $1.7B | $6.8B | ||
| Q1 24 | $1.7B | $6.7B |
| Q4 25 | 0.12× | 1.90× | ||
| Q3 25 | 0.12× | 1.89× | ||
| Q2 25 | 0.12× | 1.87× | ||
| Q1 25 | 0.12× | 1.85× | ||
| Q4 24 | 0.15× | 1.84× | ||
| Q3 24 | 0.12× | 1.88× | ||
| Q2 24 | 0.13× | 1.81× | ||
| Q1 24 | 0.14× | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $47.8M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $47.8M | ||
| Q3 25 | $14.0M | $-1.4M | ||
| Q2 25 | $6.8M | $28.0M | ||
| Q1 25 | $25.7M | $8.9M | ||
| Q4 24 | $57.9M | $37.9M | ||
| Q3 24 | $23.0M | $8.3M | ||
| Q2 24 | $27.8M | $24.8M | ||
| Q1 24 | $-8.0M | $-3.1M |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | -0.05× | ||
| Q2 25 | — | 1.00× | ||
| Q1 25 | 3.89× | 0.30× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 5.35× | 0.43× | ||
| Q2 24 | 15.44× | 0.83× | ||
| Q1 24 | — | -0.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
